Axsome Therapeutics Rallies 40% On FDA Product Label Proposal, But Analyst Remains Skeptical

Zinger Key Points
  • Axsome Therapeutics are up 40% following positive news on ASX-05 from the FDA.
  • Bank of America analyst Jason Gerberry remains skeptical on the stock.

Axsome Therapeutics Inc AXSM shares rallied 40% on Monday morning after the company received some positive news from the U.S. Food and Drug Administration regarding its AXS-05 novel treatment for MDD (depression).

What Happened? Axsome filed an 8K on Monday morning reporting the FDA has proposed a product label for ASX-05. While the market's initial reaction to the news was extremely positive, Bank of America analyst Jason Gerberry remains skeptical about ASX-05's potential commercial success.

Related Link: EXCLUSIVE: Aurora Cannabis CEO 'Absolutely Confident' Company Will Be EBITDA-Positive By Year's End

Why It's Important: Gerberry has previously modeled a relatively high 70% probability of success for ASX-05. Following the latest update, Gerberry is now projecting FDA approval for the drug in the third quarter.

"We ultimately expect AXS-05 to be approved without a restrictive REMS and assume that any PMR safety study requirements could pertain to special populations or abuse liability. However, we maintain our Underperform rating, as we are more bearish on the AXS-05 commercial launch," Gerberry said.

Related Link: EXCLUSIVE: Cannabis Debt Market Execs Talk Investment Opportunities, 'Equity-Like Returns Without The Equity Risk'

In addition to the Underperform rating, Gerberry reiterated his $29 price target for Axsome, suggesting about 12% downside from Monday morning's levels.

If AXS-05 is ultimately approved, Gerberry said investors should monitor two important factors related to the labeling and commercial approval. First, he said the nature and extent of post-market commitments will be critical. Second, Gerberry said investors should note whether or not a Risk Evaluation and Mitigation Strategy (REMS) will be required.

Benzinga's Take: At this point, it's looking good for AXS-05 to be approved sometime this year, but Gerberry points out that doesn't make Axsome stock a sure thing at current levels. If commercial uptake of AXS-05 disappoints or if a competing candidate generates significantly better data in treating depression, Axsome shares could have significant downside.

Posted In: Bank of AmericaJason GerberryAnalyst ColorNewsPrice TargetSmall CapFDAAnalyst Ratings

Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.

All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.

Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.

Rate collection and criteria: Click here for more information on rate collection and criteria.